Techpool Bio-Pharma

About Techpool Bio-Pharma

Established in 1993, Techpool Bio-Pharma Co., Ltd. operates as a key biopharmaceutical player with headquarters in Guangzhou, China. The company focuses on the research, development, manufacturing, and marketing of biologic drugs, particularly in the critical care sector. Since its founding, Techpool has grown to become a significant enterprise in the field of human-derived protein biopharmaceuticals.

As a member of the Shanghai Pharma group, Techpool has established itself as a high-tech joint venture. A significant milestone in the company's history was the transformation initiated in 2011 under the leadership of then-CEO Henry Lee, who brought over two decades of management experience from prominent pharmaceutical companies like Novartis and Eisai. This period saw the company modernize its production lines to meet China's new Good Manufacturing Practice (GMP) standards, becoming the first in Guangdong province to do so. In 2018, Takeda divested its share in Techpool to its joint venture partners.

Techpool's business model integrates the entire value chain from R&D to sales. The company generates revenue through the sale of its proprietary and co-marketed pharmaceutical products. Its primary market is China, where it has a nationwide sales and marketing network, but it also exports to other regions, including Asia, Europe, and South America. The company's client base consists of hospitals and healthcare providers within the critical care and other specialized medical fields.

The company's product portfolio centers on injectable biologic drugs. Key products include Tianpuloyan® (Ulinastatin for injection), an exclusive drug in China for treating acute pancreatitis and sepsis, and Kailikang® (Urinary Kallidinogenase for injection), a first-in-class drug for cerebral infections. Ulinastatin, in particular, has seen extensive use, with sales volumes around 11 million vials per year. Techpool also holds the exclusive distribution rights in mainland China for Bondronat (ibandronic acid), a treatment for tumor bone metastasis, through an agreement with Roche. The company's focus remains on developing and providing treatments for life-threatening conditions.